{
  "docId": "019dd923-5efe-75c0-8dff-2e87a7b85930",
  "docSlug": "d74f6dfc5c764997",
  "documentTitle": "2026 Capital Markets Day AM",
  "authorId": "Syncona",
  "authorName": "Syncona",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 30,
  "pageCount": 55,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "kpi_dashboard",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 9,
  "notes": null,
  "elementsJson": [
    "headline_text",
    "big_number",
    "icon_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5efe-75c0-8dff-2e87a7b85930/30",
  "deckHref": "/decks/019dd923-5efe-75c0-8dff-2e87a7b85930",
  "deckJsonHref": "/decks/019dd923-5efe-75c0-8dff-2e87a7b85930.json",
  "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dff-2e87a7b85930#slide-30",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Syncona has generated significant patient impact across its portfolio.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-832d-736c-a657-84cf496bad23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.03,
        "y": 0.34
      },
      "kind": "metric",
      "text": "26 Syncona portfolio companies since 2012 foundation",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "034f8db8-f161-4fde-a994-40b411277c67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.03,
        "y": 0.54
      },
      "kind": "metric",
      "text": "15 Number of companies in the portfolio today",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "057330e1-edca-4386-b96b-7fbb15416306",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.29,
        "y": 0.34
      },
      "kind": "metric",
      "text": "5 Late-stage clinical and commercial companies across the portfolio since inception",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07a33be1-b946-4521-9b06-ba00f3d881a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.2,
        "x": 0.77,
        "y": 0.505
      },
      "kind": "metric",
      "text": ">8,000 Annual US/EU cases of Adult ALL, disease targeted by Autolus' AUCATZYL",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20887e85-5a90-472e-889f-f00d987a4547",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.29,
        "y": 0.54
      },
      "kind": "metric",
      "text": "51 Clinical trials across the portfolio since inception",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24d4153c-c609-4118-b5b6-762000d4ffd7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.35,
        "y": 0.78
      },
      "kind": "metric",
      "text": "70K sqft of specialist manufacturing space built by Autolus at The Nucleus facility",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3bedafb3-8536-44cb-8abc-350abdda03d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.03,
        "y": 0.78
      },
      "kind": "metric",
      "text": "£3.7BN of capital raised for UK-based Syncona companies, including 4 NASDAQ IPOs",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "401e422c-eb2e-41c8-ac71-f9b329d12165",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.08,
        "x": 0.67,
        "y": 0.33
      },
      "kind": "metric",
      "text": "3 Phase III trials",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58eaaafa-5270-4022-b792-915c311d373b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.2,
        "x": 0.77,
        "y": 0.305
      },
      "kind": "metric",
      "text": "165K Patients diagnosed by Blue Earth's product Axumin",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a179cdc9-f7c8-4db5-aefc-dea5976905ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.08,
        "x": 0.56,
        "y": 0.33
      },
      "kind": "metric",
      "text": "2 Approved products",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a92302b2-3037-4d41-a58e-2f2234134a99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.08,
        "x": 0.61,
        "y": 0.51
      },
      "kind": "metric",
      "text": "6 Diseases with high unmet medical need",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd4bb4e0-845c-4c1e-84db-97f11e3a6737",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.67,
        "y": 0.78
      },
      "kind": "metric",
      "text": ">1,000 UK-based employees",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e175f998-378b-4609-a54c-68b2bc8a7889",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Patient impact: 165K",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-832d-736c-a657-89dbbd7564ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.8,
        "x": 0.03,
        "y": 0.955
      },
      "kind": "source-note",
      "text": "1. Source: https://www.businesswire.com/news/home/20220719005024/en/Independent-Clinical-Studies-Published-Regarding-Performance-of-Axumin-Fluciclovine-F-18-PET-Imaging-in-Patients-with-Recurrent-Prostate-Cancer-Undergoing-Androgen-Deprivation-Therapy-ADT.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac10c1c3-01a3-4931-a7b5-eebc8a243fd2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.55,
        "x": 0.03,
        "y": 0.19
      },
      "kind": "title",
      "text": "SYNCONA HAS GENERATED SIGNIFICANT PATIENT IMPACT ACROSS ITS PORTFOLIO",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b5d1ee6-88e8-42fd-add3-efbe0b6918b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.42,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Building companies with impact",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14be5327-092b-4eda-852d-63ef73a2a00c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 30,
      "from": 21,
      "beatId": "bb541e8d-587d-4c69-82a4-5441d3353d74",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The presentation then discusses Syncona's model, its approach to building companies, and its impact on patients",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}